Novavax, Inc.

Novavax, Inc. Earnings Recaps

NVAX Health Care 3 recaps
Next earnings: February 25, 2027 (estimated) · full calendar
Q3 2026 Nov 8, 2026

Novavax fell 8.2% after earnings, despite raising its full-year revenue framework and improving expense guidance. The transcript points to limited near-term visibility beyond partner milestones: Sanofi’s U.S. phase III trial is targeted for 2027, while the company describes broader partnership and pipeline opportunities as still developing.

Key takeaways
  • Sanofi’s European phase III flu/COVID combination trial triggered a $125 million milestone; Novavax expects another $75 million upon completion of manufacturing technology transfer in mid-2027.
  • Sanofi is targeting a U.S. phase III start in 2027 to support U.S. approval, leaving that opportunity dependent on future trial progress.
  • Sanofi began the 2026/2027 COVID season with Nuvaxovid in the U.S. and introduced it in select international markets; Takeda continues promoting it in Japan.
  • Novavax plans to enter the clinic with its C. diff vaccine candidate as early as next year.
  • Management said it raised its full-year revenue framework and improved expense guidance, but the transcript provides no revised figures.
Q1 2026 May 7, 2026

Shares rose 14.0% as the market rewarded Novavax’s clear progress in expanding high-value partnerships, particularly with big pharma like Pfizer and Sanofi, signaling confidence in its capital-efficient, licensing-driven growth strategy rather than direct product sales.

Key takeaways
  • Novavax signed four new material transfer agreements (MTAs) including a significant oncology MTA with a top 10 global pharma company, marking expanded collaboration in difficult cancer targets.
  • The company’s partnerships with Pfizer and Sanofi are positioned to generate billions in future milestone and royalty revenues, with Sanofi already contributing over $800 million in revenue to date.
  • Strategy emphasizes capital-efficient growth by leveraging partners’ infrastructure and investment, reducing Novavax’s operational costs while focusing on R&D-led innovation.
  • Management outlined a lean operating model aimed at driving down costs while supporting key R&D capabilities under new Head of R&D Bob Walker.
  • The outlook centers on advancing current partnerships to clinical readiness and converting MTAs into licensing agreements, supporting long-term, diversified revenue streams.
Q3 2025 Nov 6, 2025

Novavax demonstrated significant progress in Q3 2025, strengthening its partnership strategies and advancing its diversified R&D pipeline while achieving substantial cash flow, underscoring a shift towards long-term profitability and growth.

Key takeaways
  • Achieved approximately $1.1 billion in nondilutive cash flow over 8 quarters, bolstered by $800 million from partnerships.
  • Successfully secured $225 million from Sanofi-related milestones, including key regulatory approvals for Nuvaxovid.
  • Launched new early-stage R&D initiatives targeting infectious diseases and oncology, emphasizing a diversified pipeline beyond COVID-19.
  • Initiated cost-saving measures, including consolidating facilities to enhance financial strength, projected to save approximately $230 million.
  • Positioned to potentially reach non-GAAP profitability by 2028 through a revamped revenue mix driven by partnerships and royalties.